Cargando…

Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic

Dolutegravir (DTG) based dual therapies for treating PLWHIV are a standard of care nowadays. Switching to DTG and lamivudine (3TC) safety and efficacy were proven in TANGO randomized clinical trial. This multicenter retrospective study included 1032 HIV virologically suppressed patients switching to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buzón, Luis, Dueñas, Carlos, Pedrero, Roberto, Iribarren, Jose Antonio, de los Santos, Ignacio, Díaz de Santiago, Alberto, Morán, Miguel Ángel, Pousada, Guillermo, Moreno, Estela, Ferreira, Eva, Iglesias, Alicia, Martín, Cristina, Gómez, Julia, Rodríguez, Laura, Egido, Miguel, Sepulveda, María-Antonia, Troya, Jesús
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963008/ https://www.ncbi.nlm.nih.gov/pubmed/36851536 http://dx.doi.org/10.3390/v15020322

Ejemplares similares

Predict the Effects of Dolutegravir (DTG) Plus Lamivudine (3TC) on Immunological Responses in People Living with HIV (PLWHIV)
por: Troya, Jesús, et al.
Publicado: (2023)

1598. Predictive equations for immune recovery at 48 weeks of BIC/FTC/TAF treatment in Virologically Suppressed PLWHIV.
por: Tomé, Roberto Pedrero, et al.
Publicado: (2023)

1262. Dolutegravir Plus 3TC In Antiretroviral Experienced Adults: Immunovirological Outcomes In a Multicenter Retrospective Cohort In Spain
por: Buzón-Martín, Luis, et al.
Publicado: (2022)

Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
por: Dueñas-Gutiérrez, Carlos, et al.
Publicado: (2023)

1571. BIC/FTC/TAF in Virologically Suppressed PLWHIV: 48-96 weeks RETROBIC Multicenter Cohort study results.
por: Estévez, Samuel, et al.
Publicado: (2023)

Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study
por: Troya, Jesús, et al.
Publicado: (2022)

Knowledge attitude and practice of malignancies among PLWHIV in Nigeria
por: Adebamowo, Clement, et al.
Publicado: (2012)

Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen
por: Iannone, Valentina, et al.
Publicado: (2023)

Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV
por: Correa, Analú, et al.
Publicado: (2020)

Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses
por: Marije Hofstra, Laura, et al.
Publicado: (2014)

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2017)

Cervical cancer screening and treatment for PLWHIV: experiences from an innovative program in Nigeria
por: Ogunsola, Olabanjo Okunlola, et al.
Publicado: (2023)

Monkeypox outbreak in Madrid (Spain): Clinical and virological aspects
por: Orviz, Eva, et al.
Publicado: (2022)

Prevalence and predictors of metabolic syndrome among people living with human immunodeficiency virus (PLWHIV)
por: Bosho, Dula Dessalegn, et al.
Publicado: (2018)

Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible
por: Pena, M J, et al.
Publicado: (2018)

Predictors of virological failure in HIV‐1‐infected patients switching to dolutegravir maintenance monotherapy
por: Wijting, IEA, et al.
Publicado: (2018)

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
por: Wolf, Eva, et al.
Publicado: (2021)

Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV
por: Sangaré, Mohamed N’dongo, et al.
Publicado: (2020)

High Seroprevalence of IgG Antibodies to Multiple Arboviruses in People Living with HIV (PLWHIV) in Madagascar
por: Rakotomalala, Fetra Angelot, et al.
Publicado: (2023)

48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort
por: Cabello-Ubeda, Alfonso, et al.
Publicado: (2022)

2488. Virologic Failure in ART Naïve Patients Initiating on a Dolutegravir or Elvitegravir-Based Regimen
por: Wohlfeiler, Michael, et al.
Publicado: (2019)

Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2022)

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks
por: Rolle, Charlotte-Paige, et al.
Publicado: (2023)

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
por: Mills, Anthony M., et al.
Publicado: (2019)

Brief Report: Virologic Impact of the Dolutegravir Transition: Prospective Results From the Multinational African Cohort Study
por: Esber, Allahna, et al.
Publicado: (2022)

1023. Suppressed Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide vs. Dolutegravir/Lamivudine: Virologic Failure and Durability
por: Pierone, Gerald, et al.
Publicado: (2023)

DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2019)

Type 2 diabetes mellitus prevalence and risk scores in treated PLWHIV: a cross-sectional preliminary study
por: Masenga, Sepiso K., et al.
Publicado: (2019)

A discrete choice experiment to assess people living with HIV's (PLWHIV's) preferences for GP or HIV clinic appointments
por: Miners, A H, et al.
Publicado: (2017)

Physical virology: From virus self‐assembly to particle mechanics
por: Buzón, Pedro, et al.
Publicado: (2020)

Comparative Safety and Changes in Immunologic and Virologic Parameters of Dolutegravir versus Efavirenz-Based Antiretroviral Therapies Among HIV Patients: A Retrospective Cohort Study
por: Ayal, Melese Alemnew, et al.
Publicado: (2023)

Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144
por: Wang, Ruolan, et al.
Publicado: (2023)

Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis
por: Wandeler, Gilles, et al.
Publicado: (2019)

Loneliness as a mediation from social support leading to a decrease of health-related quality of life among PLWHIV
por: Qian, Zhe, et al.
Publicado: (2023)

Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single‐tablet regimen in a multicentre cohort in Spain
por: Suárez‐García, Inés, et al.
Publicado: (2021)

549. Weight and BMI Changes in HIV-Infected Virologically Suppressed Adults after Switching to an Elvitegravir- or Dolutegravir-Containing Regimen
por: Gibson, Amanda, et al.
Publicado: (2018)

Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project
por: Bagella, Paola, et al.
Publicado: (2019)

1603. Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide -the DYAD study
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2023)

Predictors of Time to Viral Load Suppression of Adult PLWHIV on ART in Arba Minch General Hospital: A Follow up Study
por: Hussen, Sultan, et al.
Publicado: (2019)

Real-Life Early Anthropometric, Lipid and Liver Changes after Direct-Acting Antiviral Therapy in PLWHIV with HCV Co-Infection
por: Ferra-Murcia, Sergio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jic140d78o1irv392m0m682cnk